Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of 桑枝总生物碱片 (WH007) in polycystic ovary syndrome
CTR20260897Phase 2Active
- Sponsor
- Wuheboao Pharmaceutical
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ramulus mori alkaloids in polycystic ovary syndrome (PCOS), sponsored by Wuheboao Pharmaceutical. Started Mar 2026; status: active.
02
Drugs
ramulus mori alkaloids
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on CTR20260897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260897.